Activist investor ups pressure on GSK’s CEO in battle over drug giant’s spinoff plan
Activist investor Elliott Management Corp. is raising the pressure on GlaxoSmithKline CEO Emma Walmsley. Here’s the latest.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
